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ABSTRACT
....................................................................................................................................................
Objective Develop a device-agnostic cloud platform to host diabetes device data and catalyze an ecosystem of software innovation for type 1
diabetes (T1D) management.
Materials and Methods An interdisciplinary team decided to establish a nonprofit company, Tidepool, and build open-source software.
Results Through a user-centered design process, the authors created a software platform, the Tidepool Platform, to upload and host T1D device
data in an integrated, device-agnostic fashion, as well as an application (“app”), Blip, to visualize the data. Tidepool’s software utilizes the
principles of modular components, modern web design including REST APIs and JavaScript, cloud computing, agile development methodology,
and robust privacy and security.
Discussion By consolidating the currently scattered and siloed T1D device data ecosystem into one open platform, Tidepool can improve access to
the data and enable new possibilities and efficiencies in T1D clinical care and research. The Tidepool Platform decouples diabetes apps from dia-
betes devices, allowing software developers to build innovative apps without requiring them to design a unique back-end (e.g., database and secu-
rity) or unique ways of ingesting device data. It allows people with T1D to choose to use any preferred app regardless of which device(s) they use.
Conclusion The authors believe that the Tidepool Platform can solve two current problems in the T1D device landscape: 1) limited access to T1D
device data and 2) poor interoperability of data from different devices. If proven effective, Tidepool’s open source, cloud model for health data inter-
operability is applicable to other healthcare use cases.
....................................................................................................................................................
Keywords: diabetes mellitus type 1, insulin infusion systems, blood glucose self-monitoring, mobile applications, decision making, computer-
assisted
BACKGROUND AND SIGNIFICANCE
Diabetes is one of the largest healthcare problems in the United
States, with an estimated 29 million people having the disease (21
million diagnosed cases).1 Each year, the United States sees 19 000
new cases of type 1 diabetes (T1D). T1D is the second most common
chronic condition in children, trailing only asthma. T1D, which requires
the replacement of insulin via subcutaneous injection, is unique
among chronic diseases in its heavy reliance upon patient self-
management. Patients make minute-to-minute decisions about their
insulin dosing based on a multitude of factors such as current blood
glucose (BG) level, food intake, and activity level. There is a very nar-
row margin for error, especially in children.2 Taking either too much or
too little insulin can cause dangerous and sometimes life-threatening
high or low BG levels. To avoid this, insulin dosing regimens must be
adjusted frequently and individually for each patient. Such personal-
ized fine-tuning requires significant effort and is seldom done.3
The introduction of insulin pumps has made it possible to deliver in-
sulin continuously and with great precision. Pumps more closely mimic
physiological insulin secretion, giving variable “basal” rates throughout
the day and delivering additional boluses for each meal or snack, or to
bring down high BG levels.4 The use of continuous glucose monitoring
(CGM) devices has allowed for tighter BG control,5–7 which has been
shown to reduce the rates of diabetes complications.8
Diabetes devices store a patient’s data, including insulin dose his-
tory, insulin pump settings, and BG values from BG meters and CGM
devices. These data can be downloaded from devices into historical
reports by patients or healthcare providers. Analyzing these reports
can help a provider or patient identify BG trends and effects of insulin
on BG levels. A patient’s insulin regimen can then be adjusted based
on this analysis combined with a patient’s recall of her activities and
life events. This individualized fine-tuning of insulin doses, known as
“flexible intensive insulin therapy,” has been shown to improve quality
of life and glycemic control in people with T1D.9 Despite this, only a
small percentage of people with T1D use these historical reports to
retrospectively review their device data and look for patterns to inform
future dosing decisions.10–12 Instead, most people with T1D use only
their most recent BG reading to make insulin dosing decisions.13
Potential reasons for this lack of retrospective review of diabetes
device data include the data silos and workflow challenges that exist
with device downloading and data interpretation. Custom cables and
proprietary software, often requiring different computer operating sys-
tems, are needed to download and view device data.14 Because
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patients may use multiple devices from different vendors to manage
their diabetes, it is often impossible for a patient to import all of her de-
vice data into one software application. Moreover, each software appli-
cation has a unique user interface and data display paradigm,14 which
would be akin to each EKG manufacturer developing their own data ac-
quisition and display method rather than conforming to the standard.
Vendors have from time-to-time partnered with each other to di-
rectly pair their devices and create device-to-device interoperability—
for example, an insulin pump from one vendor with a CGM from
another vendor.15–17 Though these pairings consolidate real-time dis-
plays to improve the patient experience, they fail to address the under-
lying issue of proprietary data silos and their impact is thus limited.
Numerous efforts have tried to facilitate an integrated download and
data display from multiple vendors’ devices.18–20 Sweetspot, targeting
physicians’ offices as customers and using kiosks in physicians’ of-
fices to upload device data, failed to achieve broad commercial suc-
cess and was acquired in 2012 by CGM vendor Dexcom.21 Diasend
sells proprietary software, offering a hardware upload hub that sends
device data to the cloud, creating an integrated data visualization.18
Glooko, first funded with venture capital in January 2012,22 has to this
point focused on devices (BG meters) and visualizations aimed at the
type 2 diabetes market.19 In 2015, however, Glooko announced it
would begin integrating insulin pumps and CGMs.23 The grant-funded
Ambulatory Glucose Profile24 is a proposed standard for the display of
data from any vendor’s CGM, rather than an integration of multiple de-
vices into one display. A different approach toward device interopera-
bility is the forthcoming set of Institute of Electrical and Electronics
Engineers (IEEE) standards for diabetes device data protocols, based
on work from the University of Toronto.24–26 Both the Ambulatory
Glucose Profile and IEEE device standards differ from companies like
Sweetspot, Diasend, and Glooko in that the standards will require im-
plementation by device vendors. Despite so many efforts, the diabetes
device data ecosystem remains fragmented and siloed.
Further fragmenting the ecosystem are the hundreds of mobile
apps developed to help patients track and review diabetes data.27–29
Apps typically do not interface with each other and apps not developed
by device makers do not connect with devices to automatically retrieve
data. Users must thus manually enter BG values and insulin doses into
each app, an inefficient, error-prone, and burdensome process.30
Vendor-developed apps that automatically upload device data, like
iBGStar, have largely served to sustain closed ecosystems rather than
enabling true interoperability.31 Most apps either lack a data export
function or export data as a document (e.g., PDF file) rather than as
discrete values. For these and other reasons, diabetes mobile apps
have as of yet failed to reach broad adoption.32,33
OBJECTIVE
Our goal was to create a cloud-based, device-agnostic software plat-
form that could download and integrate raw data from any diabetes de-
vice. Our primary aim was to facilitate easier access to these currently
siloed data. This device data interoperability would then enable the crea-
tion of an ecosystem of innovative diabetes management apps. As such,
to demonstrate the utility of our platform, our secondary aim was to de-
velop an app that would incorporate data from different devices and fa-
cilitate conversations between T1D patients and providers.
MATERIALS AND METHODS
Existing market dynamics make it difficult for the diabetes industry to
address the problem of interoperability and instead encourage proprie-
tary vertical silos of devices, data storage, and software.
Our strategy was to instead draw on the experience of the
communications industry, where companies providing proprietary and
closed internet access like Prodigy, AOL, and Compuserve gave way
to the open model of the World Wide Web.34,35 Just as cultivation of
the Internet required non-profit funding, we felt the same would be
true for an open data platform for diabetes management. We thus
formed a non-profit corporation, Tidepool (tidepool.org),36 hypothesiz-
ing that a transparent process and organizational structure were
critical to establish a new paradigm for management of diabetes
device data.
Being nonprofit ensures that Tidepool in perpetuity prioritizes inter-
operability and open access over data silos and claims on market
share. In this way, Tidepool aims to bolster the entire diabetes data
ecosystem rather than competing over existing customers. If Tidepool
is successful at catalyzing an open ecosystem with a large selection of
diabetes apps, this may grow the overall device market, allowing all
companies to sell more devices. The nonprofit, transparent structure
facilitates a collaborative effort between our interdisciplinary team of
academic endocrinologists, clinical informaticists, software devel-
opers, user interface experts, and technology entrepreneurs, most of
whom either have T1D or family members with T1D. The nonprofit
model has also helped Tidepool garner enthusiastic support from the
T1D community at large, including patients, families, advocacy
groups, and device makers.
A potential disadvantage of non-profit status is the inability to secure
venture capital funding. Because venture capitalists have focused diabe-
tes investments on the larger, more lucrative type 2 diabetes market
rather than T1D, this concern is minimized for Tidepool. Tidepool’s
startup funding has come from private philanthropists and granting
agencies. Rather than relying on these sources indefinitely, Tidepool be-
lieves it can operate as a self-sustaining non-profit business, generating
revenue through data hosting services. There are early indicators that
this model can be successful.
In addition to choosing a non-profit status, our second major stra-
tegic decision was to create open-source software. We were inspired
by the “open mHealth” model,37 believing that T1D is a particularly
well-suited use case. The use of open-source software is consistent
with our goals to reduce barriers to entry for new app developers, to
foster collaboration, and to create software that is safe and secure.
Identified factors favoring the use of open-source software in health-
care include: allowing universal access to the software, ensuring pub-
lic scrutiny of the code, providing users the ability to add functionality
and fix bugs without waiting for a company to do it, providing a toolkit
that allows researchers to expand upon the software, and improving
development efficiency.38 Because Tidepool will continually employ
developers to maintain the software, code contributions from the open
source community will augment rather than sustain the platform.
Tidepool chose to use the Berkeley Software Distribution open-source
license,39 a highly permissive license that allows third parties to lever-
age and repurpose any or all Tidepool code, maximizing the code’s
potential impact. To date, nine employees and fifteen open source
contributors have created code for Tidepool.
Tidepool’s development process is transparent beyond being
open-source. All planning and technical documentation is openly pub-
lished at GitHub.40 Third parties are free to use Tidepool’s code to run
their own private installations, or they can apply for access to use
Tidepool’s hosted data store for their own applications, a model used
by many successful companies like WordPress.41 Tidepool’s nonprofit
model and open ecosystem stand in contrast to the corporate philoso-
phies and structures taken by SweetSpot, Diasend, and Glooko. Our
hypothesis is that achieving broad impact on T1D device interoperabil-
ity may require this unique combination of attributes.
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The collaboration between academia and technologists has thus
far proven critical, providing a broad set of resources. The University
of California, San Francisco (UCSF) offered a healthcare-specific entre-
preneurship course where we formulated potential business models.42
UCSF’s Center for Digital Health Innovation is working to integrate
Tidepool with its electronic health record (EHR). Clinical researchers
on our team reinforced the need to prioritize validation and evaluation
of the Tidepool Platform and subsequent apps on meaningful patient-
oriented and clinical outcomes, building the necessary structure into
the product. Reciprocally, Tidepool’s technical and product design
team have provided expertise not typically available in-house at aca-
demic institutions. Together, we aimed to surge forward with the agil-
ity of a startup company to create a modern, user-friendly system,
while developing the meaningful medical content and clinical work-
flows necessary for a useful health tool.
RESULTS
The Tidepool Platform
The Tidepool Platform provides a hub for patients’ diabetes device
data, along with open access for third-party apps to communicate
with the platform using RESTful application program interfaces (APIs).
The Tidepool Platform is device-agnostic, ingesting data from any ven-
dor’s device(s) and then allowing any app to connect to the platform to
use that data (Figure 1). This eliminates the current one-to-one rela-
tionship between T1D device hardware and software (Figure 2). As the
foundation for future development of T1D apps, the Platform was built
to handle “back-end” components such as security and authentica-
tion, data storage, and HIPAA compliance. Thus, software developers
can focus on building engaging and useful apps without having to
worry about developing a new back-end themselves. Of note,
Tidepool’s software is still in an early stage of implementation, cur-
rently in use by a small group of beta testers and in a pilot study at
the UCSF as well as by clinics associated with the ReplaceBG study
coordinated by the Jaeb Center for Health Research.
Blip App
In parallel with development of the Platform, Tidepool created Blip, the
first app built on the Platform. Blip combines an individual patient’s
data from multiple devices into a single integrated display, allowing
data visualization and interpretation. In the example in Figure 3, data
was combined from a Medtronic insulin pump, Dexcom CGM device,
and a Bayer Contour glucose meter. “Sticky notes” indicate comments
entered via a patient-facing mobile app about food, exercise, or other
relevant life events. The integrated visual interface allows providers or
patients to look for relationships between carbohydrate intake, insulin
boluses, and rising or falling glucose levels.
The Tidepool Platform: Engineering and Architecture Principles
In addition to being open-source, we consider 6 other engineering
principles as core to the Tidepool Platform.
Small, Modular Pieces
Code built in small, modular pieces makes each element more man-
ageable to design, build, and test, as well as allowing easy isolation in
the case of a problem.43 In an open-source environment, having small
pieces makes it easier for many developers to contribute code. The
Tidepool Platform is currently composed of 16 different components in
5 groups (Table 1), working together to create the desired functions of
the system (Figure 4).
Modern web design
Tidepool uses modern software architecture (see Table 2), including
designing the software around RESTful principles,44 which the
Agency for Healthcare Research and Quality (AHRQ) recently called the
“foundation” of an interoperable healthcare system.45 In a RESTful
system, major system components are both accessed by and commu-
nicate using standard (rather than proprietary) web protocols. This
makes it easier to design and deploy the pieces individually and inde-
pendently, which aids in robustness and ease of maintenance. It also
reduces the complexity for client software, as there are mature tools
in every programming language for communicating with RESTful APIs.
This standard toolkit lowers the barriers to development.
Tidepool’s server systems use a set of interoperating RESTful pro-
tocols that are publicly accessible online.46 Tidepool’s apps use those
protocols to communicate with the servers. A JavaScript library that
encapsulates client communications with the Tidepool Platform is also
freely available online.40
Cloud-computing
Tidepool’s “Platform as a Service” model relies on cloud-computing
(Figure 5). The cloud model, with centralized data storage and online
access to computing resources, allows access to data from any place,
at any time, from any source.47–49 Cloud computing is still nascent in
healthcare despite being standard in many other business applica-
tions. Schweitzer et al.50 noted that cloud-based healthcare software
could be more efficient and less expensive than traditional enterprise
software, could promote interoperability and data exchange, and
Figure 1: Diabetes device data flow with Tidepool Platform.
Figure 2: Diabetes device data flow before Tidepool
Platform.
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would be more responsive to changes. By relying on an intermediary
vendor, cloud computing’s potential limitations include security and
privacy risks as well as the risk of service interruption.
Client software products for the Platform are built as web applications
using JavaScript and HTML. Storing and delivering software over the
web means that users can always access the most recent software ver-
sion, seamlessly benefiting from the latest advancements and bug fixes.
Agile software development
Tidepool uses agile software development methodology, which priori-
tizes the flexibility to adapt to changing product needs over adhering
to a pre-specified project plan as is done in “waterfall” development
models.51–54 Healthcare customer needs are complicated and often
poorly understood at the outset. Agile methodology allows many
stakeholders (i.e., clinicians, researchers, patients, caregivers, and IT
departments) to shape software development over time.
Tidepool’s development cycles are limited to 2-week time periods.
Any functionality estimated to require more development time is broken
into sub-deliverables. This helps Tidepool try to quickly deliver functionality
to end-users, often with multiple new software releases delivered in a 2-
week period. These 2-week periods are referred to as “sprints.”55 The
sprint methodology gives Tidepool a structure to maintain course when
priorities remain constant or adapt quickly as priorities or user needs shift.
User-centered design
User-centered design involves iterative cycles during the design and
development process that involve user input at every stage.56 While
this approach can “maximize user motivation and engagement, reduce
system failure or dramatic revisions, and provide greater feasibility
and sustainability,” one review found that only 18% of mobile diabetes
apps studied described a user-centered design process.30
By contrast, user-centered design has been a core process in de-
veloping the Tidepool Platform and its initial app for data visualization,
Blip. In its first 18 months, Tidepool has conducted 502 interviews
with patients, clinicians, researchers, device makers, and software de-
velopers. With few exceptions, these meetings were conducted either
face-to-face or via video conference, consistent with “Lean Startup”
methodology.57 As Tidepool meets with users and perceives the need
for new functionality, an application or sub-component of an applica-
tion is coded into a functioning prototype. Over the course of several
weeks, that prototype is shared with dozens of constituents. Feedback
is collected in real time and additions are made daily, so often no two
testers will experience the identical prototype.
Early prototype versions are also shared with patients and their
families in a “beta” release. The beta is distributed via the web, along
with assignments for the user to complete that provide structured
feedback. Through April 2015, 49 patients and families had been
Figure 3: Blip App screenshot.
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invited to participate in the beta, with 32 invitees participating and
submitting feedback. Concurrent with this user-centered design pro-
cess, we have been collecting user data and feedback on the Blip app
as part of an IRB-approved pilot study at UCSF.
Security and privacy
The Platform uses a government-standard algorithm for encryption
and data are encrypted both at rest and during transport.58 User data,
such as log-on information, is stored and encrypted separately from
patient data, which includes health and demographic data. All pieces
of the system are located behind a firewall (Figure 4); only the router
is accessible to the global Internet. An app server delivers client appli-
cations like Blip to individual computers, which then communicate to
the Tidepool cloud to provide user services and medical data.
The Platform has undergone security assessments following
the National Institute of Standards and Technology controls59 at 2
large healthcare systems. These include questions about: platform ar-
chitecture, data management practices (policies for storage and ac-
cess, encryption, and data breaches), restrictions on external access
(firewalls, access keys, and security roles and permissions), and third-
party vendors used (including business associate arrangements).
Tidepool has implemented the Platform in a way that meets all
federal Health Insurance Portability and Accountability Act (HIPAA)
requirements and has signed business associate agreements with
UCSF and with Amazon Web Services (required because Tidepool uses
Amazon’s cloud servers).
DISCUSSION
The Tidepool Platform offers many opportunities to improve technolo-
gies that enable clinical care and research for T1D (summarized in
Table 3 and described below).
Potential Advantages for Diabetes App Development
Apps built on the Tidepool Platform can offer unique front-end func-
tionality while sharing a common data structure and back-end
(Figure 6). This open access to a shared back-end lowers the barrier
to entry for developers with creative ideas for new diabetes apps.
Apps can easily be interoperable with other apps and developers will
have broader access to data and other functionalities than they would
have if they built a standalone app. Interoperability of health technol-
ogy can potentially improve patient safety, protect against lost and
missing data, and improve efficiency of care.60
Other industries have similarly benefited from a move from closed
and proprietary ecosystems to open, standards-based, multi-vendor
ecosystems.14 This “co-opetition” provides greater flexibility due to
more potential device permutations, lower costs, and movement by
companies toward higher value activities.61
Table 1: Tidepool Platform code modules.
Code
Grouping
Group Function Key Components
of Each Group
Server
management
Manages communication
between the various
components of the
Tidepool Platform
• Server assignment
• Discovery
• Request routing
User data
storage
Manages users and
communications to
and from the
user databases
• Management of user
login data
• User metadata and
demographics
• Authorization
• Messages and notes
Medical data
storage
Stores and
retrieves medical
data
• Medical data uploader
• Medical data
processing and
ingestion
• Medical data retrieval
Libraries Collections of useful
functions to make
it easier to work
with the code
• Time and date
manipulation
• Communications with
other bits of the API
• Assistance for software
developers
Applications
and their
support
The parts of the
system that are
visible to the
end user
• Application for viewing
and reviewing diabetes
data in context (Blip)
• Visualization library
• Mobile-compatible
communications app
Figure 4: Tidepool Platform architectural diagram.
Table 2: The Tidepool technology stack.
Function Technology or Service Used
Hosting Amazon Web Services (HIPAA-compliant
dedicated instances)
Data storage MongoDB, Amazon S3
Server architecture JavaScript/NodeJS, Golang
Key server libraries Express, restify, lodash, async, rxjs
Client architecture React
Data visualization D3
HIPAA, Health Insurance Portability and Accountability Act
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Potential Benefits to Clinical Care
The Tidepool Platform will allow people with diabetes to identify and
use apps that uniquely address their individual needs,28 choosing
apps based on functionality rather than based on whichever input de-
vice(s) they are using. Promoting connections between apps enables
the inclusion of data sources, such as food and activity tracking apps
or heart rate sensors, which are not typically used alongside BG or in-
sulin data. Putting these data alongside more traditional diabetes de-
vice data improves context, facilitating the review of life events that
coincide with a diabetes-related event such as a hypoglycemic
episode. Prior evidence has shown that integrating contextual data is
helpful in T1D management.62
Cloud-based apps built for the Tidepool Platform, like Blip, can facili-
tate the sharing of diabetes device data and ongoing communication be-
tween patient and provider. This communication is often lacking,
creating a barrier to improved glycemic control.13,28 More frequent clini-
cian review of patient-generated diabetes data along with feedback to
the patient has been shown to improve hemoglobin A1c.63 Developing
rapid feedback loops between a patient and provider could facilitate
“teachable moments,”64 whereby providers could guide patients toward
learning how specific life events impact glycemic control. Integration of
diabetes device data with EHRs could facilitate these rapid feedback
loops by placing diabetes device data into healthcare provider work-
flows. Having a single open-source platform like Tidepool could facilitate
EHR integration since health IT departments would only need to inte-
grate one back-end data source as opposed to creating a unique custom
integration for each vendor device and application.
As development of closed-loop “artificial pancreas” systems pro-
gresses,65,66 there is a need for safety and monitoring software. The
Tidepool Platform can fill this need, providing cloud-based data hosting,
visualization, and analytic tools that would allow patients, providers, or
regulatory agencies to track data from the artificial pancreas.
Potential Benefits to Diabetes Research
A cloud-based platform provides researchers with opportunities that
were previously difficult to attain or unavailable with installed client soft-
ware. Cloud-based storage allows data to be stored once but accessed
by any number of authorized users. Thus, for example, Tidepool might
give patients the ability to contribute their data to an anonymized re-
search database. Any researcher would then be able to access this
comprehensive dataset of openly available, high-quality, contextualized
Table 3: Potential clinical and research advantages of an open diabetes platform.
Current State Open Platform
Near one-to-one relationship between device and application Any application can use data from any device
Mobile apps require manual data entry by the user, leading to user burden and
transcription errors
Mobile apps automatically access and collect device data
A provider must learn to interpret data presented in each unique software appli-
cation and visualization format from each device vendor (or choose only one de-
vice to prescribe to their patients)
A provider selects and gains expertise using one software applica-
tion of choice while still allowing patients the freedom to choose
to use whichever devices they prefer
Patients may use devices (e.g., one pump and one continuous glucose monitoring
device) from different vendors but are forced to sacrifice data interoperability
Patients who choose any permutation of devices are able to use
device data in an integrated fashion
Mobile app developers must each develop a unique vertical product stack includ-
ing back-end features (e.g., secure and private data storage)
App developers can focus on developing front-end, user-facing
apps that integrate with the back-end of the Tidepool Platform
Diabetes software only uses and shows data from diabetes specific hardware Diabetes software can incorporate data from any source, including
trackers for fitness/activity, heart rate, and food
Device companies must devote resources to software development Device companies can focus efforts and resources on hardware,
their area of expertise
Clinical research studies utilizing devices are restricted in the permutations of de-
vices they can use
Clinical research studies can use any combination of devices
Developing new clinical decision algorithms in research studies requires many
slow iterations of testing, refinement, and then pushing out the updated algorithm
for testing again
Researchers can more efficiently study clinical algorithms, push-
ing the algorithms out to users through the cloud and rapidly get-
ting feedback about efficacy
Researchers must manually collect data for each new retrospective study they
conduct
Researchers can access and query a comprehensive clinical data-
set that is already collected
Figure 5: Tidepool Platform cloud diagram.
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diabetes device data, allowing novel research questions to be an-
swered.67 Such a research database could be used to help simulate and
test artificial pancreas algorithms before they are applied in patients.
Using the Tidepool Platform for data collection and hosting would
relieve clinical researchers of the need to independently set up a data
collection system for each research study, improving efficiency and
decreasing research costs. This infrastructure is already being used to
support a multi-center clinical study involving 275 patients.68
Clinical researchers will have new opportunities to evaluate the effi-
cacy of T1D software. The current one-to-one bond between device and
software has created few opportunities to compare the efficacy of T1D
software independent of the devices collecting the data. In studies show-
ing improved quality of life and clinical outcomes for users of insulin
pumps and CGM devices, device-software combinations have been ana-
lyzed rather than individual components.69–73 Only 2 published studies
have compared patients on insulin pumps who used the vendor-provided
software to those on insulin pumps who did not use the software.11,74
Researchers could use the Tidepool Platform and cloud analytics
tools to evaluate user engagement with and efficacy of specific com-
ponents or combinations of components of diabetes apps.75 These
more precise insights are currently lacking in most published diabetes
mobile app studies,30 which tend to follow the “black box” model of
evaluation.33 Usability testing methods not typically seen in healthcare
might be possible, such as “A/B testing,”76 where researchers can
perform repeated usability tests of small variations in their apps with a
high frequency of iterations.
CONCLUSION
Both the Tidepool Platform and its development process, if proven to
be effective, can serve as models for future healthcare technology in-
novation. The Tidepool Platform’s open software code is adaptable for
use beyond T1D in other chronic diseases that rely on patient-
generated multi-sourced data, such as type 2 diabetes, asthma, or
congestive heart failure.
Tidepool’s success would illustrate that an “open mHealth” model
can facilitate interoperability and would suggest that proprietary ven-
dor data silos are a restrictive and outdated model.37 Tidepool, though
still in its early stages, has already catalyzed a vibrant dialogue and
meaningful contributions from T1D advocacy groups, healthcare pro-
viders, researchers, software developers, and device manufacturers
worldwide. Tidepool has stimulated a virtuous cycle in the T1D device
ecosystem, as a majority of diabetes device manufacturers have com-
mitted to opening their data protocols to Tidepool. The future imple-
mentation of data protocol standards14 will create more efficiency in
this open innovation ecosystem, obviating Tidepool of the need to im-
plement device protocols one at a time.
We hope that apps built on the Tidepool Platform—like Blip—
can facilitate better self-management and clinical diabetes
outcomes through improved data accessibility and improved feed-
back and communication between patient and provider. We foresee
that the Tidepool Platform will spur the development of many useful
new apps for T1D beyond Blip, meeting patient and provider needs in
ways that were not previously possible when data was trapped in
silos.
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